Sanofi Ventures invests in top tier biotherapeutic and digital health entrepreneurs who focus on helping patients and transforming the healthcare system.
Investment Type: Venture Capital
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| 27.04.2023 | Therini Bi... | therinibio.com | $92M | - |
Mentions in press and media 11
| Date | Title | Description |
| 12.10.2025 | Star Therapeutics: $125 Million Series D Raised For Developing Antibodies For Bleeding Disorders | Star Therapeutics, an innovative clinical-stage biotechnology company, is dedicated to discovering and developing cutting-edge antibodies aimed at treating bleeding disorders and other medical conditions. The company recently announced the ... |
| 09.10.2025 | Expedition Therapeutics: $165 Million Series A Raised For Advancing DPP1 Inhibitor For COPD | Expedition Therapeutics, a biotechnology company dedicated to developing therapies for novel inflammatory and respiratory diseases, has closed an oversubscribed and upsized Series A financing round, raising $165 million. This financing roun... |
| 01.10.2025 | Star Therapeutics Raises $125M in Series D Financing | Star Therapeutics, a San Francisca, CA-based clinical stage biotechnology company discovering and developing antibodies for bleeding disorders and other diseases, raised $125M Series D funding. The round was co-led by Sanofi Ventures and Vi... |
| 29.09.2025 | Sanofi: $625 Million Commitment Announced To Advance Investments In Biotech | Sanofi Ventures, the dedicated corporate venture capital arm of the global biopharmaceutical company Sanofi, has announced a significant expansion of its investment capacity. The company has committed an additional $625 million over multipl... |
| 18.09.2025 | Character Biosciences Expands Series B Extension | Character Biosciences, Jersey City, NJ-based precision medicine company, raised an undisclosed amount in Series B extension. Backers included Sanofi Ventures. The company intends to use the funds to further advance the clinical development ... |
| 14.09.2025 | Odyssey Therapeutics: $213 Million Series D Closed For Advancing Autoimmune Disease Pipeline | Odyssey Therapeutics, a clinical-stage biopharmaceutical company, has closed an oversubscribed $213 million Series D financing to accelerate the development of its portfolio of medicines targeting autoimmune and inflammatory diseases. The r... |
| 25.04.2025 | Granite Bio debuts with $100 million to tackle autoimmune diseases | Granite Bio is a biotechnology company developing first-in-class antibodies that target the root causes of a variety of inflammatory, autoimmune and fibrotic conditions. Its pipeline comprises two lead candidates. GRT-001 depletes pro-infl... |
| 10.02.2025 | AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing | Sydney, Australia – 3 February 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing. This ... |
| 11.01.2023 | Sanofi Ventures Announces Multi-Year Capital Commitment from Sanofi; Evergreen Fund Increases to $750M | Sanofi Ventures has announced an additional multi-year commitment from Sanofi (EURONEXT: SAN and NASDAQ: SNY), with an increase in capital to more than $750m to the evergreen venture fund. In addition to serving as a financial partner to to... |
| 14.12.2017 | NEA-backed Curisium Raises $3.5M Seed | Curisium, a healthcare technology and services company that enables innovative contracting at scale via its blockchain-based platform, announced today it has raised $3.5M in seed financing from Flare Capital Partners, New Enterprise Associa... |
Show more